

AWARENESS OF MEDICAL APPLICATIONS OF GINGKO BILOBA AMONG DENTAL STUDENTS

Nithyanandham Masilamani¹, Dhanraj Ganapathy²

Abstract

Herbal medicines reflect a significant portion of new interest in alternative therapies and Ginkgo biloba (GB) features significantly throughout this regard. The GB concentrate and any of its constituents is already thoroughly researched in terms of its impact on behavioral, physiological and psychological consequences linked with neurological and vascular conditions. The purpose of this survey was for assessing the awareness of medical applications of Ginkgo biloba amongst dental students. A cross sectional survey was conducted with a self-administered questionnaire with 10 queries circulated among 100 dental students. The questionnaire assessed the awareness about Ginkgo bilobatherapy in medical applications, their anti dementia properties, anti alzheimer properties, anti aging activity, anti inflammatory activity, and its mechanism of action and side effects. The responses were recorded and analysed. 8% of the respondents were aware of the medical applications of Ginkgo biloba therapy, 6% were aware of the anti dementia activity of Ginkgo biloba therapy, 5% were aware of anti alzheimer properties of Ginkgo biloba therapy, 6% were aware of anti aging properties of Ginkgo biloba therapy, 5% were aware of anti inflammatory properties of Ginkgo biloba therapy, 5% were aware mechanism of action and side effects of Ginkgo biloba therapy. The awareness about the usage of Ginkgo biloba therapy in medicinal applications is low among dental students. Increased awareness programs and sensitization and continuing dental education programs along with greater importance to the curricular modifications can further enhance knowledge and awareness about Ginkgo biloba therapy.

Keywords: Awareness, Ginkgo biloba, students, dementia

Introduction

Phyto products represent a considerable segment of the present enthusiasm for elective medicines and Ginkgo biloba (GB) figures noticeably in this intrigue. Ginkgo biloba is taken from the leaves of the Maiden Hair sapling, that is believed to live 2,000 to 4,000 years. (Isah, 2015) The belief in the medicinal potential of GB can

¹ Tutor, Department of Prosthodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, India.

² Professor & Head of Department, Department of Prosthodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, India, Email: ghanrajmganapathy@yahoo.co.in

be traced back nearly 5,000 years to ancient China, where healer Chen Nong (2767 to 2687 BC) described the rehabilitative abilities of this plant. The indications covered heart and lung ailments with evidence that drawing in its steam and drinking up its tea is palliative to all asthma and also bronchitis (DeFeudis & Drieu, 2000).

Herbal medicines reflect a significant portion of new interest in alternative therapies and Ginkgo biloba (GB) features significantly throughout this regard. The GB concentrate and any of its constituents is already thoroughly researched in terms of its impact on behavioral, physiological and psychological effects related to neural and vascular disorders. Specific capacities and disorders include deficit memory, reaction time, attention, concentration, psychomotor ability, impairment, mind-set, performance, and pace preparation data. GB has also been used tentatively to compensate for the deficiencies and symptoms of dementia and age-related alzheimer, terrible mental illness, coma, multi-infarct dementia, cortical coronary artery disease, neurological dysfunction, cerebral oedema, emotional stress, glutamate detrimental effects, addiction, apoptosis, tinnitus, sexual deterioration, and macular degeneration. (Kleijnen & Knipschild, 1992; Lin et al., 1999) The purpose of this survey was for assessing the awareness of medical applications of Ginkgo biloba amongst dental students.

Materials and method

A cross sectional survey was conducted with a self-administered questionnaire with 10 queries circulated among 100 dental students. The questionnaire assessed the awareness about Ginkgo bilobatherapy in medical applications, their anti dementia properties, anti alzheimer properties, anti aging activity, anti inflammatory activity, and its mechanism of action and side effects. The responses were recorded and analysed.

Results

8% of the respondents were aware of the medical applications of Ginkgo biloba therapy (Fig 1). 6% were aware of the anti dementia activity of Ginkgo biloba therapy (Fig 2), 5% were aware of anti alzheimer properties of Ginkgo biloba therapy (Fig 3), 6% were aware of anti aging properties of Ginkgo biloba therapy (Fig 4), 5% were aware of anti inflammatory properties of Ginkgo biloba therapy (Fig 5), 5% were aware mechanism of action and side effects of Ginkgo biloba therapy (Fig 6).

Fig 1: Awareness of the medical applications of Gingko biloba therapy




Fig 2: Awareness of the anti dementia activity of Gingko biloba therapy




Fig 3: Awareness of the anti alzheimer activity of Gingko biloba therapy




Fig 4: Awareness of the anti aging activity of Gingko biloba therapy




Fig 5: Awareness of the anti inflammatory activity of Gingko biloba therapy





Fig 6: Awareness of the mechanism and side effects of Gingko biloba therapy



Discussion

EGb 761 is a metabolic agent known to be responsible for Gingko biloba herb ingredients normalized to 24 per cent ginkgo-flavone glycosides and 6 per cent terpenoid. Significant components of EGb 761 (> 0.1 per cent)

are: flavonol monoglycosides (e.g. quercetin-3-Q-glucoside, quercetin-3-O-rhamnoside, and 3'-O-methylmyricetin-3-0-glucoside), flavonol diglycosides, flavonol triglycosides, coumarosides, natural acids, and steroids liable for the different system of action. (Li & Wong, 1997) (Moreau et al., 1988)

Vasomodulatory impact: GBE has been shown to have constraining or delayed effects on vessels in a state-subordinated manner in animal model. GBE increases the aggregation of norepinephrine and induces Ca^{2+} dependent chocking of discrete aorta as well as vena cava. Notwithstanding increased thoughtful incitement, the constrictor impact may likewise include reduced catechol-O-methyltransferase (COMT) movement, or fractional reuptake hindrance. Rather than constrictive components, the late effects have all the earmarks of being endothelium-subordinate. Alternative methodologies could include inhibitory activity of MAO, release of prostacycline (PGI₂), percent beta-adrenoceptor agonism, enhanced intracellular sequestration of Ca^{2+} , rapid increase of nitric oxide synthase, decreased expression of nitric oxide (NO) or lowered lipid peroxidation. (Kobuchi et al., 1997)

Metabolic consequences: GBE in smooth muscles induces an increase in glucose consumption and glycogen mixture in a subjugated manner. Research on hypoxic endothelial cells show that GBE and bilobalide can prolong the onset of hypoxic glycolysis by extending out the period of adenosine triphosphate (ATP). However, the basic instruments remain muddled. Actuating factor operation antiplatelet. GBE tends to inhibit platelet aggregation by increasing endothelial-inferred thrombolytic groups. Ginkgolide B aspect of the terpene division has antiplatelet enacting factor (PAF) characteristics. In addition, significantly following the pre-incubation of PAF with platelets, ginkgolide B provides a virtually total withdrawal of bound PAF. This result is important due to the PAF's argument in the pathogenesis of oedema, inflammation and hypercoagulable conditions. The properties of antioxidants.

GBE has been shown to cause the pulverization of various free radicals, including OH, O^{•-}, diphenylpicrylhydrazide radical, including adriamycin radical. It can rummage NOs and decrease nitrate levels in a dose-dependent way, offering further help for its job as wide range scrounger." In vitro and in vivo studies show that the flavonous portion of GBE can inhibit lipid peroxidation and platelet aggregation. & The flavonous segment can interfere with the ability of ginkgo to protect physiological structures from receptive reactive oxygen. This may be useful in reinforcing the effects of blood lipoprotein oxidation that give rise to evidence and accumulation of atherosclerotic plaques accompanying hypoperfusion-reperfusion in hypoxic states. (Spinnewyn et al., 1987) (Maccocci et al., 1994) (Brunello et al., 1985)

Focal Effects: GBE applies transmitter and receptor effects that are likely to interfere with radical search / restraint, hemodynamic / metabolic equilibrium, PAF resistance, MAO and COMT impediment, alpha-agonist, receptor thickness modification, and NO synthase hindrance. Proof shows that GB can alter and restore a variety of focal phases and conditions. GBE has induced increases in norepinephrine production in rodents, alpha-2-receptor density, muscarinic acetylcholine (mACh) and serotonin (5HT) receptor surface area, but also decreases beta-adrenoceptor density. (Brunello et al., 1985) (Brunello et al., 1985; Hellegouarch et al., 1985)

GB appears to be applying its effects through its cellular reinforcement and toward PAF activity, despite its stimulatory influence on cerebrovascular tone, receptor function, glucose absorption and electroencephalographic function. Dose Based effects have been observed under accompanying conditions: subjective hindrance, cerebrovascular insufficiency, tinnitus, hypoxia, vestibular bloats as well as aging.(Brailowsky et al., 1991)(Hoerr & Nacu, 2016)

GBE is linked to extended prostacycline amalgamation and the hindrance of radicals induced by arachidonic corrosive cascade. GB has restricted the frequency of personalized cell movement through optimized rodent cerebellar neurons. Overall, GBE appears to have a protective effect on rodent cerebellar neurons during oxidative damage.(Le Bars et al., 1997)

Ginkgo has been widely covered and has demonstrated no adverse drug effects. It should be noted, in any case, that because ginkgo has the properties of a monoamine oxidase (MAO) inhibitor, it can have a synergistic effect when coupled with other MAO inhibitor drugs. Since ginkgo acts as an antiplatelet acting factor, warning should be used when guided to anticoagulants..(Sachikonye & Mukanganyama, 2016; Ven & van de Ven, 1997)

Conclusion

The awareness about the usage of Ginkgo biloba therapy in medicinal applications is low among dental students.Increased awareness programs and sensitization and continuing dental education programs along with greater importance to the curricular modifications can further enhance knowledge and awareness about Ginkgo biloba therapy.

References

1. Brailowsky, S., Montiel, T., Hernández-Echeagaray, E., Flores-Hernández, J., & HernáNdez-Pineda, R. (1991). Effects of a Ginkgo biloba extract on two models of cortical hemiplegia in rats. In *Restorative Neurology and Neuroscience* (Vol. 3, Issue 5, pp. 267–274). <https://doi.org/10.3233/rnn-1991-3505>
2. Brunello, N., Racagni, G., Clostre, F., Drieu, K., & Braquet, P. (1985). Effects of an extract of Ginkgo Biloba on noradrenergic systems of rat cerebral cortex. In *Pharmacological Research Communications* (Vol. 17, Issue 11, pp. 1063–1072). [https://doi.org/10.1016/0031-6989\(85\)90112-2](https://doi.org/10.1016/0031-6989(85)90112-2)
3. DeFeudis, F., & Drieu, K. (2000). Ginkgo Biloba Extract (EGb 761) and CNS Functions Basic Studies and Clinical Applications. In *Current Drug Targets* (Vol. 1, Issue 1, pp. 25–58). <https://doi.org/10.2174/1389450003349380>
4. Hellegouarch, A., Baranès, J., Clostre, F., Drieu, K., Braquet, P., & DeFeudis, F. V. (1985). Comparison of the contractile effects of an extract of Ginkgo biloba and some neurotransmitters on rabbit isolated vena cava. In *General Pharmacology: The Vascular System* (Vol. 16, Issue 2, pp. 129–132). [https://doi.org/10.1016/0306-3623\(85\)90049-7](https://doi.org/10.1016/0306-3623(85)90049-7)
5. Hoerr, R., & Nacu, A. (2016). Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial. In *Open Access Journal of Clinical Trials* (p. 1). <https://doi.org/10.2147/oajct.s93531>

6. Isah, T. (2015). Rethinking Ginkgo biloba L.: Medicinal uses and conservation. In *Pharmacognosy Reviews* (Vol. 9, Issue 18, p. 140). <https://doi.org/10.4103/0973-7847.162137>
7. Kleijnen, J., & Knipschild, P. (1992). Ginkgo biloba. In *The Lancet* (Vol. 340, Issue 8828, pp. 1136–1139). [https://doi.org/10.1016/0140-6736\(92\)93158-j](https://doi.org/10.1016/0140-6736(92)93158-j)
8. Kobuchi, H., Droy-Lefaix, M. T., Christen, Y., & Packer, L. (1997). Ginkgo biloba extract (EGb 761): inhibitory effect on nitric oxide production in the macrophage cell line RAW 264.7. *Biochemical Pharmacology*, 53(6), 897–903.
9. Le Bars, P. L., Katz, M. M., Berman, N., Itil, T. M., Freedman, A. M., & Schatzberg, A. F. (1997). A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. *JAMA: The Journal of the American Medical Association*, 278(16), 1327–1332.
10. Li, C. L., & Wong, Y. Y. (1997). The bioavailability of ginkgolides in Ginkgo biloba extracts. *Planta Medica*, 63(6), 563–565.
11. Lin, R. Y., Duggan, R. M., & Rotblatt, M. D. (1999). Book Reviews Herbal Remedies, 2nd edition, Edited by Thomas Brendler, Dr. Joerg Gruenwaid, Christof Jaenicke Deutscher Apotheker Verlag, Stuttgart, 1997, 99.00; ISBN: 3-7692-2221-0 The Five Elements of Self-Healing: Using Chinese Medicine for Maximum Immunity, Wellness, and Health By Jason Elias, L.Ac, and Katherine Ketcham Harmony Books, New York, 1998, 422 pp, 27.50; ISBN 0-517-70487-0 (hardcover) The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines, Mark Blumenthal (Senior Editor) American Botanical Council, Austin, TX 1998. ISBN: 0-965555-0-X; 684 pp.; 165.00. PDR for Herbal Medicines Medical Economics Co., Montvale, NJ; 1st ed., ISBN: 1-56363-292-6; approx. 900 pp.; 59.95. 1998. In *The Journal of Alternative and Complementary Medicine* (Vol. 5, Issue 2, pp. 213–217). <https://doi.org/10.1089/acm.1999.5.213>
12. Marcocci, L., Maguire, J. J., Droy-Lefaix, M. T., & Packer, L. (1994). The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. *Biochemical and Biophysical Research Communications*, 201(2), 748–755.
13. Moreau, J. P., Eck, C. R., McCabe, J., & Skinner, S. (1988). Absorption, Distribution, and Excretion of Tagged Ginkgo Biloba Leaf Extract in the Rat. In *Rökan* (pp. 37–45). https://doi.org/10.1007/978-3-642-73686-5_4
14. Sachikonye, M., & Mukanganyama, S. (2016). Antifungal and Drug Efflux Inhibitory Activity of Selected Flavonoids Against *Candida albicans* and *Candida krusei*. In *Journal of Biologically Active Products from Nature* (Vol. 6, Issue 3, pp. 223–236). <https://doi.org/10.1080/22311866.2016.1231078>
15. Spinnewyn, B., Blavet, N., Clostre, F., Bazan, N., & Braquet, P. (1987). Involvement of platelet-activating factor (PAF) in cerebral post-ischemic phase in Mongolian gerbils. *Prostaglandins*, 34(3), 337–349.
16. Ven, L. L. M. van de, & van de Ven, L. L. M. (1997). Age-Dependent Differences in the Efficacy and Tolerability of Different Classes of Antihypertensive Drugs. In *Clinical Drug Investigation* (Vol. 14, Issue 1, pp. 16–22). <https://doi.org/10.2165/00044011-199714010-00003>